ProShare Advisors LLC Acquires 5,181 Shares of Eli Lilly and Company $LLY

Key Points

• ProShare Advisors increased its Eli Lilly stake by 4%, purchasing 5,181 shares to bring its holdings to 134,385 shares valued at approximately $155.5 million. Institutional investors collectively own 82.53% of the stock.
• Eli Lilly reported strong quarterly results, with EPS of $7.48 and revenue of $24.4 billion, up 38.6% year over year and ahead of analyst expectations. The company also declared a $1.73 quarterly dividend, equivalent to a 0.5% annual yield.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and several firms raising price targets as high as $1,650. However, investors face risks from the stock’s premium valuation, potential pricing pressure and heavy reliance on GLP-1 medicines.

ProShare Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 134,385 shares of the company's stock after purchasing an additional 5,181 shares during the quarter. ProShare Advisors LLC's holdings in Eli Lilly and Company were worth $155,494,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. BlackRock Inc. boosted its position in Eli Lilly and Company by 1.6% in the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company's stock valued at $81,009,981,000 after buying an additional 1,046,558 shares in the last quarter. State Street Corp boosted its stake in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company's stock worth $43,438,262,000 after purchasing an additional 605,752 shares during the period. Bank of America Corp DE bought a new stake in Eli Lilly and Company in the 2nd quarter valued at approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company's stock worth $8,647,153,000 after purchasing an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in shares of Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company's stock worth $6,550,587,000 after buying an additional 400,538 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,412.06 on Tuesday. The company has a 50-day simple moving average of $1,200.81 and a 200 day simple moving average of $1,094.25. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,449.68. The company has a market capitalization of $1.33 trillion, a PE ratio of 45.83, a price-to-earnings-growth ratio of 1.73 and a beta of 0.46.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping analysts' consensus estimates of $5.71 by $1.77. The company had revenue of $24.40 billion for the quarter, compared to analysts' expectations of $22.58 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company's revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $7.02 EPS. On average, research analysts predict that Eli Lilly and Company will post 35.18 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.5%. Eli Lilly and Company's payout ratio is 22.46%.

Analysts Set New Price Targets

LLY has been the subject of a number of recent analyst reports. Bank of America reiterated a "buy" rating and issued a $1,497.00 price target on shares of Eli Lilly and Company in a research note on Friday. Guggenheim boosted their price objective on shares of Eli Lilly and Company from $1,273.00 to $1,284.00 and gave the company a "buy" rating in a research report on Friday, September 18th. BMO Capital Markets reiterated an "outperform" rating and issued a $1,650.00 price target on shares of Eli Lilly and Company in a research note on Friday. Cantor Fitzgerald upped their price target on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an "overweight" rating in a research report on Monday. Finally, UBS Group increased their target price on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a "buy" rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $1,404.14.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Another strong quarter and higher guidance: Third-quarter revenue rose roughly 39% year over year to $24.4 billion, beating expectations, while adjusted EPS also exceeded estimates. Strong demand for Mounjaro and Zepbound led Lilly to raise its full-year outlook. Eli Lilly Just Delivered Another Blowout Quarter
• Positive Sentiment: Analyst price-target increases: Cantor Fitzgerald raised its target to $1,600 and maintained an “overweight” rating. Other firms, including JPMorgan, also boosted targets, reflecting continued confidence in Lilly’s earnings outlook. Cantor Fitzgerald price target
• Neutral Sentiment: Commercial reorganization: Lilly is combining its U.S. and international commercial operations into one division. The move could improve coordination and execution globally, but its financial effect is not yet clear. Lilly combines commercial divisions
• Negative Sentiment: Pricing and growth concerns: Medicare’s GLP-1 Bridge program and lower realized drug prices may pressure revenue and margins. Analysts also warn that growth could moderate after exceptionally strong results, while one-time revenue benefits may not recur. Lilly’s First Full Medicare Quarter
• Negative Sentiment: High expectations and concentration risk: With about two-thirds of revenue tied to its leading GLP-1 medicines and the shares trading at a premium valuation, investors may be taking profits and demanding evidence that rapid growth can continue. Eli Lilly: Softer Growth Ahead

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at $1,808,325.26. This trade represents a 56.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock valued at $15,958,170 in the last 90 days. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company's portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer's disease.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.